BioXcel Therapeutics, Inc. Interest Expense
BioXcel Therapeutics, Inc. (BTAI) reported Interest Expense of $3.61 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-09.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2024-05-09
- BioXcel Therapeutics, Inc. interest expense for the quarter ending 2024-03-31 was $3.61M, a 7.13% increase year-over-year.
- BioXcel Therapeutics, Inc. interest expense for the quarter ending 2023-12-31 was $3.44M, a 17.64% increase year-over-year.
- BioXcel Therapeutics, Inc. interest expense for the quarter ending 2023-09-30 was $3.25M, a 12.11% decline year-over-year.
- BioXcel Therapeutics, Inc. interest expense for the quarter ending 2023-06-30 was $3.26M, a 105.49% increase year-over-year.
- BioXcel Therapeutics, Inc. interest expense for fiscal 2023 was $13.31M, a 62.11% increase from fiscal 2022.
- BioXcel Therapeutics, Inc. interest expense for fiscal 2022 was $8.21M, a 20432.50% increase from fiscal 2021.
- BioXcel Therapeutics, Inc. interest expense for fiscal 2021 was $40.00K, a 48.15% increase from fiscal 2020.
- BioXcel Therapeutics, Inc. interest expense for fiscal 2020 was $27.00K, a 35.00% increase from fiscal 2019.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $3.61M 10-Q · filed 2024-05-09 | $7.04M derived: sum of 2 quarters · filed 2024-05-09 | $10.29M derived: sum of 3 quarters · filed 2024-05-09 | $13.55M derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | $3.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $6.69M derived: sum of 2 quarters · filed 2024-03-22 | $9.95M derived: sum of 3 quarters · filed 2024-03-22 | $13.31M 10-K · filed 2024-03-22 |
| 2023-09-30 | $3.25M 10-Q · filed 2023-11-14 | $6.51M derived: sum of 2 quarters · filed 2023-11-14 | $9.88M 10-Q · filed 2023-11-14 | $12.80M derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-06-30 | $3.26M 10-Q · filed 2023-08-14 | $6.63M 10-Q · filed 2023-08-14 | $9.55M derived: sum of 3 quarters · filed 2024-05-09 | $13.25M derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-03-31 | $3.37M 10-Q · filed 2024-05-09 | $6.29M derived: sum of 2 quarters · filed 2024-05-09 | $9.99M derived: sum of 3 quarters · filed 2024-05-09 | $11.57M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $2.92M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-22 | $6.62M derived: sum of 2 quarters · filed 2024-03-22 | $8.21M derived: sum of 3 quarters · filed 2024-03-22 | $8.21M 10-K · filed 2024-03-22 |
| 2022-09-30 | $3.70M 10-Q · filed 2023-11-14 | $5.29M derived: sum of 2 quarters · filed 2023-11-14 | $5.29M 10-Q · filed 2023-11-14 | $5.30M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $1.59M 10-Q · filed 2023-08-14 | $1.59M 10-Q · filed 2023-08-14 | $1.60M derived: sum of 3 quarters · filed 2023-08-14 | $1.61M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $7.00K 10-Q · filed 2023-05-09 | $13.00K derived: sum of 2 quarters · filed 2023-05-09 | $24.00K derived: sum of 3 quarters · filed 2023-05-09 | $40.00K derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $6.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $17.00K derived: sum of 2 quarters · filed 2023-03-16 | $33.00K derived: sum of 3 quarters · filed 2023-03-16 | $40.00K 10-K · filed 2023-03-16 |
| 2021-09-30 | $11.00K 10-Q · filed 2021-11-10 | $27.00K derived: sum of 2 quarters · filed 2022-08-11 | $34.00K 10-Q · filed 2021-11-10 | $38.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-06-30 | $16.00K 10-Q · filed 2022-08-11 | $23.00K 10-Q · filed 2022-08-11 | $27.00K derived: sum of 3 quarters · filed 2022-08-11 | $32.00K derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $7.00K 10-Q · filed 2022-05-09 | $11.00K derived: sum of 2 quarters · filed 2022-05-09 | $16.00K derived: sum of 3 quarters · filed 2022-05-09 | $28.00K derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $9.00K derived: sum of 2 quarters · filed 2022-03-11 | $21.00K derived: sum of 3 quarters · filed 2022-03-11 | $27.00K 10-K · filed 2022-03-11 |
| 2020-09-30 | $5.00K 10-Q · filed 2021-11-10 | $17.00K derived: sum of 2 quarters · filed 2021-11-10 | $23.00K 10-Q · filed 2021-11-10 | -$4.00K derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $12.00K 10-Q · filed 2021-08-10 | $18.00K 10-Q · filed 2021-08-10 | -$9.00K derived: sum of 3 quarters · filed 2021-08-10 | $9.00K derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $6.00K 10-Q · filed 2021-05-10 | -$21.00K derived: sum of 2 quarters · filed 2021-05-10 | -$3.00K derived: sum of 3 quarters · filed 2021-05-10 | |
| 2019-12-31 | -$27.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12 | -$9.00K derived: sum of 2 quarters · filed 2021-03-12 | $20.00K 10-K · filed 2021-03-12 | |
| 2019-09-30 | $18.00K 10-Q · filed 2020-11-12 | $47.00K 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |